Evidence map›Paper›PMID 37483815›Full record

ArticleHeliyon2023

NLRP3 inflammasome inhibition of OP9 cells enhance therapy for inflammatory bowel disease.

Yutong Chen, Weicheng Meng, Guangming Ren, Ning An, Jing Zhang, Zhixin Liu, Xiaoshuang Wu, Wen Yin, Xingbin Hu, Zheng Liu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yutong ChenDepartment of Transfusion Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Weicheng MengDepartment of Transfusion Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Guangming RenDivision of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, 710032, China.
Ning AnDepartment of Transfusion Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Jing ZhangDepartment of Transfusion Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Zhixin LiuDepartment of Transfusion Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Xiaoshuang WuDepartment of Transfusion Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Wen YinDepartment of Transfusion Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Xingbin HuDepartment of Transfusion Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Zheng LiuKobilka Institute of Innovative Drug Discovery, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, China.
Fan FengDivision of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, 710032, China.
Yaozhen ChenDepartment of Transfusion Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) are becoming more popular in therapy. Therefore, in-depth studies on mesenchymal stem cells in therapy are urgently needed. However, the difficulty in culturing and propagating MSCs

Indexed as

IL-1βInflammatory bowel diseaseNLRP3 inflammasomeOP9 cellPyroptosis

Identifiers

PMID37483815
PMCPMC10362138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.